Table 3.
Characteristics of the study population after propensity score matching.
| Vitamin D | No vitamin D | p | |
|---|---|---|---|
| N | 577 | 577 | |
| Age (years) | 72 (64,79) | 72 (64,79) | 0.9 |
| Gender, n | |||
| Female | 292 | 306 | 0.4 |
| Male | 285 | 271 | |
| Weight (kg) | 82 (66,99) | 80 (66,97) | 0.6 |
| Vital signs | |||
| HR | 84 (74,97) | 83 (74,97) | 0.8 |
| MAP, mmHg | 76 (70,83) | 75 (70,84) | 0.4 |
| Respiratory rate (breaths/min) | 19 (17,22) | 19 (17,22) | 0.9 |
| Temperature (°C) | 37 (36,37) | 37 (36,37) | 0.8 |
| SpO2, % | 96 (94,97) | 96 (94,98) | 0.3 |
| Laboratory parameters | |||
| Hemoglobin, g/dL | 9.8 (8.5,11.4) | 9.7 (8.3,11.3) | 0.3 |
| RBC count, 109/L | 3.7 (3.2,4.1) | 3.6 (3.1,4.1) | 0.6 |
| Hematocrit, % | 31.7 (27.2,35.9) | 30.7 (26.3,35.5) | 0.1 |
| Platelet, 109/L | 200 (146,256) | 201 (141,273) | 0.9 |
| WBC count, 109/L | 11 (8,15) | 12 (8,15) | 0.5 |
| Anion gap, mg/dL | 15 (13,17) | 15 (13,17) | 0.9 |
| Bicarbonate, mg/dL | 24 (21,28) | 24 (22,28) | 0.9 |
| Bun, mg/dL | 24 (16,41) | 24 (16,40) | 0.7 |
| Calcium, mg/dL | 8.6 (8.1,9) | 8.6 (8.2,9.0) | 0.4 |
| Chloride, mmol/L | 100 (95,105) | 101 (96,105) | 0.7 |
| Creatinine mg/dL | 1.1 (0.8,1.9) | 1.1 (0.8,1.8) | 0.9 |
| Glucose, mmol/L | 136 (109,170) | 134 (111,163) | 0.8 |
| Sodium, mg/dL | 139 (135,141) | 138 (136,141) | 0.4 |
| Potassium, mg/dL | 4.3 (4.0,4.8) | 4.3 (4.0,4.7) | 0.7 |
| INR | 1.3 (1.1,1.5) | 1.3 (1.1,1.5) | 0.9 |
| PT | 14 (12,16) | 14 (12,16) | 0.9 |
| Severity of illness | |||
| SOFA score | 5 (2,8) | 5 (2,8) | 0.5 |
| APS III score | 48 (37,62) | 47 (35,62) | 0.4 |
| OASIS | 32 (27,39) | 32 (26,37) | 0.4 |
| Comorbidities | |||
| Myocardial infarct, n | 130 | 121 | 0.5 |
| Congestive heart failure, n | 332 | 325 | 0.7 |
| Rheumatic disease, n | 36 | 37 | 0.9 |
| Peptic ulcer disease, n | 17 | 25 | 0.2 |
| Liver disease, n | 59 | 74 | 0.2 |
| Diabetes, n | 242 | 231 | 0.5 |
| Renal disease, n | 204 | 191 | 0.4 |
| Malignant cancer, n | 86 | 86 | 1 |
| Ventilator use, n | 165 | 165 | 1 |
| RRT use, n | 40 | 33 | 0.4 |
| Vasopressor use, n | 45 | 38 | 0.4 |
| Mortality | |||
| In-hospital mortality, n | 62 | 81 | 0.09 |
| ICU-mortality, n | 33 | 51 | 0.04 |
INR, international normalized ratio; PT, prothrombin time; RRT, renal replacement therapy.